Published in Cell Mol Gastroenterol Hepatol on January 20, 2017
Polyethylene glycol microspheres loaded with irinotecan for arterially directed embolic therapy of metastatic liver cancer. World J Gastrointest Oncol (2017) 0.75
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 40.30
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
Cancer statistics, 2016. CA Cancer J Clin (2016) 32.95
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med (2004) 18.93
Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell (2009) 18.31
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg (1999) 14.31
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
APC mutations occur early during colorectal tumorigenesis. Nature (1992) 9.50
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol (2009) 9.24
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet (2007) 9.23
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol (2011) 8.66
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med (2016) 8.53
Cancer stem cells: models and concepts. Annu Rev Med (2007) 8.06
Microsatellite instability in colorectal cancer. Gastroenterology (2010) 7.39
Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol (2007) 4.95
Liver resection for colorectal metastases. J Clin Oncol (1997) 4.88
Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res (1977) 4.59
Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet (2003) 3.89
Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet (1994) 3.38
Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34
Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med (1996) 2.95
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol (2013) 2.94
Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol (1992) 2.86
Challenges in circulating tumour cell research. Nat Rev Cancer (2014) 2.81
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch (2008) 2.78
Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet (2015) 2.76
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology (2006) 2.63
Stromal contribution to the colorectal cancer transcriptome. Nat Genet (2015) 2.59
The chromosomal instability pathway in colon cancer. Gastroenterology (2010) 2.59
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol (2006) 2.29
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer (2016) 2.19
The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med (2013) 2.18
Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med (1987) 2.15
Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology (1989) 2.03
Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell (2014) 2.00
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity (2016) 1.96
EMT and MET in metastasis: where are the cancer stem cells? Cancer Cell (2012) 1.94
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol (2016) 1.91
Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology (2014) 1.84
Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One (2014) 1.83
Fusion between Intestinal epithelial cells and macrophages in a cancer context results in nuclear reprogramming. Cancer Res (2011) 1.73
A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer (1992) 1.68
Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg (2011) 1.57
Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology (2014) 1.57
Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer (1983) 1.57
Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res (2012) 1.51
The Basis of Oncoimmunology. Cell (2016) 1.47
B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell (2014) 1.43
BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer (2014) 1.32
microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol (2013) 1.31
miRNA in plasma exosome is stable under different storage conditions. Molecules (2014) 1.29
Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. Oncotarget (2014) 1.25
miR-Test: a blood test for lung cancer early detection. J Natl Cancer Inst (2015) 1.24
Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. Mol Cancer (2014) 1.15
Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer (2015) 1.13
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med (2016) 1.11
Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol (1983) 1.10
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol (2014) 1.07
Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget (2014) 1.05
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol (2015) 1.04
KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer (2014) 1.02
Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Res (2014) 0.93
Exosome-mediated transfer of miR-222 is sufficient to increase tumor malignancy in melanoma. J Transl Med (2016) 0.92
Detection of tumour DNA in serum of colorectal cancer patients. Scand J Clin Lab Invest (1997) 0.91
Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care. Clin Cancer Res (2016) 0.90
Screening options and recommendations for colorectal cancer. Clin Colon Rectal Surg (2009) 0.89
Colorectal cancer: molecular mutations and polymorphisms. Front Oncol (2013) 0.89
Path toward prognostication and prediction: an evolving matrix. J Clin Oncol (2011) 0.86
miRNA Stability in Frozen Plasma Samples. Molecules (2015) 0.84
Clinical significance of pancreatic circulating tumor cells using combined negative enrichment and immunostaining-fluorescence in situ hybridization. J Exp Clin Cancer Res (2016) 0.83
Detection and Clinical Significance of Circulating Tumor Cells in Colorectal Cancer-20 Years of Progress. Mol Med (2015) 0.83
Exosomal miRNAs as cancer biomarkers and therapeutic targets. J Extracell Vesicles (2016) 0.83
Macrophage-tumor cell fusions from peripheral blood of melanoma patients. PLoS One (2015) 0.82
Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. J Surg Oncol (2016) 0.81
Detection of microsatellite alterations in the DNA isolated from tumor cells and from plasma DNA of patients with lung cancer. Ann N Y Acad Sci (2000) 0.81
Current strategies using hepatic arterial infusion chemotherapy for the treatment of colorectal cancer. Clin Colorectal Cancer (2005) 0.81
Microsatellite abnormalities in plasma of patients with breast carcinoma: concordance with the primary tumour. J Clin Pathol (1999) 0.81
Diminished expression of CRHR2 in human colon cancer promotes tumor growth and EMT via persistent IL-6/Stat3 signaling. Cell Mol Gastroenterol Hepatol (2015) 0.80
Clinical significance of circulating DNA microsatellite markers in plasma of melanoma patients. Ann N Y Acad Sci (2000) 0.80
A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases. Clin Cancer Res (2016) 0.79
DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens. Curr Drug Metab (2011) 0.78
Epigenetic inactivation of the novel candidate tumor suppressor gene ITIH5 in colon cancer predicts unfavorable overall survival in the CpG island methylator phenotype. Epigenetics (2014) 0.78
Exosomes from human colorectal cancer induce a tumor-like behavior in colonic mesenchymal stromal cells. Oncotarget (2016) 0.78
Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. Clin Colorectal Cancer (2016) 0.76